Cambridge, United Kingdom
Maxion Therapeutics is a health-tech startup founded in 2020 in the United Kingdom. The company focuses on drug discovery, employing its innovative KnotBody technology combined with in vitro display techniques to develop therapeutic candidates targeting ion channels and GPCR proteins.
With a strategic focus on the intersection of Health and Wellness and Information Technology, Maxion Therapeutics exemplifies next-gen drug discovery's potential to address complex medical challenges. The company's vision captures attention with its slogan: "Ion channel and GPCR drug discovery using innovative KnotBody technology."
The startup secured a significant financial milestone with a $72.00M Series A investment on March 17, 2025. This funding round attracted prominent investors, including General Catalyst, BGF, British Patient Capital, Monograph Capital, Solasta Ventures, Eli Lilly and Company, and LifeArc Ventures. This diverse investor base underlines strong confidence in Maxion's capacity to innovate in the therapeutics domain.
